Jason Tong

Mr. Jason Tong

University of Oxford
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in eLife
Verified
Journal Article
Open access
DJDillon Jevon
Dillon Jevon
KDKylie Deng
Kylie Deng
NHNicole Hallahan
Nicole Hallahan
KKKrish Kumar
Krish Kumar
JTJason Tong
Jason Tong
PTPeter Thorn
Peter Thorn
A developing understanding suggests that spatial compartmentalisation in pancreatic β cells is critical in controlling insulin secretion. To investigate the mechanisms, we have developed live-cell subcellular imaging methods using the mouse organotypic pancreatic slice. We demonstrate that the organotypic pancreatic slice, when compared with isolated islets, preserves intact β-cell structure, and enhances glucose-dependent Ca2+ responses and insulin secretion. Using the slice technique, we have discovered the essential role of local activation of integrins and the downstream component, focal adhesion kinase (FAK), in regulating β cells. Integrins and FAK are exclusively activated at the β-cell capillary interface and using in situ and in vitro models we show their activation both positions presynaptic scaffold proteins, like ELKS and liprin, and regulates glucose-dependent Ca2+ responses and insulin secretion. We conclude that FAK orchestrates the final steps of glucose-dependent insulin secretion within the restricted domain where β-cell contact the islet capillaries.

15 March 2020 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
WMWei Ma
Wei Ma
JCJenny Chang
Jenny Chang
JTJason Tong
Jason Tong
UHUda Ho
Uda Ho
Belinda YauBelinda Yau
Belinda Yau
PTPeter Thorn
Peter Thorn
F-actin dynamics are known to control insulin secretion, but the point of intersection with the stimulus-secretion cascade is unknown. Here, using multiphoton imaging of β cells isolated from Lifeact-GFP transgenic mice, we show that glucose stimulation does not cause global changes in subcortical F-actin. Instead, we observe spatially discrete and transient F-actin changes around each fusing granule. This F-actin remodelling is dependent on actin nucleation and is observed for granule fusion induced by either glucose or high potassium stimulation. Using GFP-labelled proteins, we identify local enrichment of Arp3, dynamin 2 and clathrin, all occurring after granule fusion, suggesting early recruitment of an endocytic complex to the fusing granules. Block of Arp2/3 activity with drugs or shRNA inhibits F-actin coating, traps granules at the cell membrane and reduces insulin secretion. Block of formin-mediated actin nucleation also blocks F-actin coating, but has no effect on insulin secretion. We conclude that local Arp2/3-dependent actin nucleation at the sites of granule fusion plays an important role in post-fusion granule dynamics and in the regulation of insulin secretion.

19 August 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
ABAnne de Bray
Anne de Bray
ARAnna G. Roberts
Anna G. Roberts
SASarah Armour
Sarah Armour
JTJason Tong
Jason Tong
CHChristiane Huhn
Christiane Huhn
DHDavid Hodson
David Hodson
Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test daLUXendin and daLUXendin+, non-lipidated and lipidated fluorescent GLP1R/GIPR dual agonist probes, and use them to visualize cellular targets. daLUXendins are potent GLP1R/GIPR dual agonists that advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cells. Systemic administration of daLUXendin strongly labels GLP1R+ and GIPR+ neurons in circumventricular organs characterized by an incomplete blood–brain barrier but does not penetrate the brain beyond labelling seen with single (ant)agonists. At the single-molecule level, daLUXendin targets endogenous GLP1R–GIPR nanodomains, which differ in organization and composition from those targeted by a single agonist. daLUXendins reveal dual agonist targets in the pancreas and brain and exclude a role for brain penetration in determining the superior efficacy of dual agonists, shedding new light on different modes of action of dual agonists versus single agonists.

3 June 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MCMegan E. Capozzi
Megan E. Capozzi
DBDavid Bouslov
David Bouslov
ASAshot Sargsyan
Ashot Sargsyan
MCMichelle Y. Chan
Michelle Y. Chan
ACAlex Chen
Alex Chen
JCJonathan E. Campbell
Jonathan E. Campbell
The incretin peptides glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors coordinate β cell secretion that is proportional to nutrient intake. This effect permits consistent and restricted glucose excursions across a range of carbohydrate intake. The canonical signaling downstream of ligand-activated incretin receptors involves coupling to Gαs protein and generation of intracellular cAMP. However, recent reports have highlighted the importance of additional signaling nodes engaged by incretin receptors, including other G proteins and β-arrestin proteins. Here, the importance of Gαs signaling was tested in mice with conditional, postdevelopmental β cell deletion of Gnas (encoding Gαs) under physiological and pharmacological conditions. Deletion of Gαs/cAMP signaling induced immediate and profound hyperglycemia that responded minimally to incretin receptor agonists, a sulfonylurea, or bethanechol. While islet area and insulin content were not affected in Gnas βcell–/– , perifusion of isolated islets demonstrated impaired responses to glucose, incretins, acetylcholine, and IBMX In the absence of Gαs, incretin-stimulated insulin secretion was impaired but not absent, with some contribution from Gαq signaling. Collectively, these findings validate a central role for cAMP in mediating incretin signaling, but also demonstrate broad impairment of insulin secretion in the absence of Gαs that causes both fasting hyperglycemia and glucose intolerance.

8 September 2021 in Coatings
Verified
Journal Article
Open access
PDF file
CTClara Tran
Clara Tran
NHNicole Hallahan
Nicole Hallahan
EKElena Kosobrodova
Elena Kosobrodova
JTJason Tong
Jason Tong
PTPeter Thorn
Peter Thorn
MBMarcela Bilek
Marcela Bilek
Implant devices containing insulin-secreting β-cells hold great promise for the treatment of diabetes. Using in vitro cell culture, long-term function and viability are enhanced when β-cells are cultured with extracellular matrix (ECM) proteins. Here, our goal is to engineer a favorable environment within implant devices, where ECM proteins are stably immobilized on polymer scaffolds, to better support β-cell adhesion. Four different polymer candidates (low-density polyethylene (LDPE), polystyrene (PS), polyethersulfone (PES) and polysulfone (PSU)) were treated using plasma immersion ion implantation (PIII) to enable the covalent attachment of laminin on their surfaces. Surface characterisation analysis shows the increased hydrophilicity, polar groups and radical density on all polymers after the treatment. Among the four polymers, PIII-treated LDPE has the highest water contact angle and the lowest radical density which correlate well with the non-significant protein binding improvement observed after 2 months of storage. The study found that the radical density created by PIII treatment of aromatic polymers was higher than that created by the treatment of aliphatic polymers. The higher radical density significantly improves laminin attachment to aromatic polymers, making them better substrates for β-cell adhesion.

16 August 2024 in Research Square
Verified
Preprint
Open access
PDF file
DHDavid Hodson
David Hodson
ABAnne de Bray
Anne de Bray
JTJason Tong
Jason Tong
CHChristiane Huhn
Christiane Huhn
KRKilian Roßmann
Kilian Roßmann
JBJohannes Broichhagen
Johannes Broichhagen
Dual agonists targeting the glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for type 2 diabetes and overweight. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test Tirzepa3 and Tirzepa5, fluorescent GLP1R/GIPR dual agonist probes. Tirzepa3 and Tirzepa5 have similar pharmacological profiles to tirzepatide, but advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. Both probes specifically label GLP1R and GIPR in cells and tissue. Tirzepa3 and Tirzepa5 label all major rodent and human pancreatic islet cells, with signal intensity beta cells > alpha cells = delta cells. Systemic administration of Tirzepa5 strongly labels the median eminence, area postrema and other circumventricular organs characterized by an incomplete blood-brain barrier, but does not readily penetrate into the brain beyond this. Upon intracerebroventricular administration in the brain, Tirzepa5 co-localizes widely with GLP1R + and GIPR + neurons, with evidence of uptake by ventricle-lining cells in the 3rd ventricle. At the single molecule level, Tirzepa5 targets endogenous GLP1R-GIPR nanodomains, which differ in organization and composition to those targeted by single agonist. Tirzepa3 and Tirzepa5 thus reveal dual agonist targets in the pancreas and brain, and further inform the different modes of action of dual agonists versus single agonists.